Pharmaceuticals

Pfizer, the world's biggest drug company, says it paid 4,500 doctors and other medical professionals about $20 million total in professional fees for services like consulting and speaking on behalf of the company, in just the last six months of 2009. During the same period, Pfizer also paid $15.3 million to 250 academic medical centers and other research groups for clinical trials.

Despite proclaiming a need to cut medical costs, the Senate health care reform bill contains a provision that will benefit large drug companies while hurting manufacturers of generic drugs. As it is now written, the bill will keep less-expensive generic drugs from entering the market for fully 12 years, far longer than the five to seven years President Barack Obama had advocated. The concession to Big Pharma companies, which manufacture expensive brand-name drugs, follows an $80 billion agreement made earlier this year between the White House and large drug makers like Merck and Pfizer, who promised to support President Obama's health reform plan, cut drug prices and pay additional taxes to help expand health insurance coverage over the next 10 years. Kathleen Jaeger, President and CEO of the Generic Pharmaceutical Association, said the health reform bill passed by the Senate " ... unfortunately, amounts to a treasure trove to brand drug companies who stand to make enormous profits from health care reform -- putting brand drug profits over patients ... With generics saving the health care system one billion dollars every three days, Congress should be looking at increasing, not decreasing, access to safe effective and affordable generic and biogeneric medicines."

Dick Armey, who was the Republican Majority Leader of the U.S. House of Representatives between 1995 to 2002, has been doing well for himself as the Chairman of FreedomWorks, a conservative lobby group. Meredith Simons reports that, according to the group's tax filings for 2008, Armey was paid $550,000. “I don't apologize for my paycheck. I'd like to think I'm worth it," he said.

"Faced with declining sales for Gardasil, the controversial -- and so far only -- vaccine for prevention of human papillomavirus, Merck & Co. is planning to boost the drug's visibility during the key back-to-school shopping period beginning this month," reports Advertising Age.